Range uncertainty reductions in proton therapy and resulting improvements in quality-adjusted life expectancy (QALE) for head-and-neck cancer patients.

IF 3.3 3区 医学 Q2 ENGINEERING, BIOMEDICAL
Sebastian Tattenberg, Peilin Liu, Anthony Mulhem, Xiaoda Cong, Christopher Thome, Cornelia Hoehr, Xuanfeng Ding
{"title":"Range uncertainty reductions in proton therapy and resulting improvements in quality-adjusted life expectancy (QALE) for head-and-neck cancer patients.","authors":"Sebastian Tattenberg, Peilin Liu, Anthony Mulhem, Xiaoda Cong, Christopher Thome, Cornelia Hoehr, Xuanfeng Ding","doi":"10.1088/1361-6560/add07d","DOIUrl":null,"url":null,"abstract":"<p><p><i>Objective</i>. Due to higher dose conformality to the target, proton radiotherapy for cancer has received rapidly-growing interest. However, uncertainties in the<i>in vivo</i>proton range and methods to reduce them remain active areas of research. Based on 20 patients with head-and-neck cancer, this study aims to quantify the benefits of proton range uncertainty reductions in terms of the resulting improvements in quality-adjusted life expectancy (QALE).<i>Approach</i>. For each patient, two different proton therapy treatment plans were created, which assumed a current clinical range uncertainty of approximately 3.5% (IMPT<sub>3.5%</sub>) and a potentially achievable range uncertainty of 1.0% (IMPT<sub>1%</sub>). A Markov model considering the probability of tumor control and the development of xerostomia, larynx edema, secondary cancer, and/or metastases as well as death from primary cancer, secondary cancer, metastases, or unrelated causes was constructed, and for every patient and treatment plan, 10 000 simulations of the patient's entire lifetime from the time of treatment until death were performed.<i>Main results.</i>A 3.5%-1% range uncertainty reduction increased QALE by up to 0.4 quality-adjusted life years (QALYs) in the nominal and up to 0.6 QALY in the worst-case scenario, equivalent to 4.8 months and 7.2 months of life in perfect health. This was largely the result of a reduction in healthy tissue toxicity rates, which were reduced by up to 8.5 percentage points (pp) and 10.0 pp in the nominal and worst-case scenario, respectively.<i>Significance</i>. The benefits of a 3.5%-1% range uncertainty reduction in 20 patients with head-and-neck cancer were quantified in terms of the associated improvement in QALE. The highest QALE improvements were observed in patients in the top quartile of youngest patients at the time of treatment, due to the longer potential lifespan over which prevented healthy tissue toxicities would have impacted the patients' quality of life.</p>","PeriodicalId":20185,"journal":{"name":"Physics in medicine and biology","volume":"70 10","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Physics in medicine and biology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1088/1361-6560/add07d","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective. Due to higher dose conformality to the target, proton radiotherapy for cancer has received rapidly-growing interest. However, uncertainties in thein vivoproton range and methods to reduce them remain active areas of research. Based on 20 patients with head-and-neck cancer, this study aims to quantify the benefits of proton range uncertainty reductions in terms of the resulting improvements in quality-adjusted life expectancy (QALE).Approach. For each patient, two different proton therapy treatment plans were created, which assumed a current clinical range uncertainty of approximately 3.5% (IMPT3.5%) and a potentially achievable range uncertainty of 1.0% (IMPT1%). A Markov model considering the probability of tumor control and the development of xerostomia, larynx edema, secondary cancer, and/or metastases as well as death from primary cancer, secondary cancer, metastases, or unrelated causes was constructed, and for every patient and treatment plan, 10 000 simulations of the patient's entire lifetime from the time of treatment until death were performed.Main results.A 3.5%-1% range uncertainty reduction increased QALE by up to 0.4 quality-adjusted life years (QALYs) in the nominal and up to 0.6 QALY in the worst-case scenario, equivalent to 4.8 months and 7.2 months of life in perfect health. This was largely the result of a reduction in healthy tissue toxicity rates, which were reduced by up to 8.5 percentage points (pp) and 10.0 pp in the nominal and worst-case scenario, respectively.Significance. The benefits of a 3.5%-1% range uncertainty reduction in 20 patients with head-and-neck cancer were quantified in terms of the associated improvement in QALE. The highest QALE improvements were observed in patients in the top quartile of youngest patients at the time of treatment, due to the longer potential lifespan over which prevented healthy tissue toxicities would have impacted the patients' quality of life.

质子治疗范围不确定性的降低和头颈癌患者质量调整预期寿命(QALE)的改善
目标。由于质子放射治疗具有较高的剂量与靶标的一致性,因此受到越来越多的关注。然而,体内质子范围的不确定性和减少它们的方法仍然是研究的活跃领域。基于20例头颈癌患者,本研究旨在量化质子范围不确定性降低在质量调整预期寿命(QALE)方面的益处。对于每个患者,创建了两种不同的质子治疗方案,假设当前临床范围不确定性约为3.5% (IMPT3.5%),潜在可实现范围不确定性为1.0% (IMPT1%)。我们构建了一个马尔可夫模型,考虑肿瘤控制的概率、口干、喉水肿、继发性癌症和/或转移的发展以及原发癌症、继发性癌症、转移或不相关原因导致的死亡,并对每个患者和治疗方案进行了10,000次从治疗到死亡的患者整个生命周期的模拟。主要的结果。3.5%-1%的范围不确定性降低可使QALE在名义情况下最多增加0.4个质量调整生命年(QALYs),在最坏情况下最多增加0.6个质量调整生命年,相当于完全健康的4.8个月和7.2个月的生命。这主要是健康组织毒性率降低的结果,在名义和最坏情况下分别降低了8.5个百分点和10.0个百分点。根据相关的QALE改善,对20例头颈癌患者的不确定性范围降低3.5%-1%的益处进行了量化。在最年轻的患者中,最年轻的患者在治疗时观察到最高的QALE改善,因为更长的潜在寿命会阻止健康组织毒性影响患者的生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Physics in medicine and biology
Physics in medicine and biology 医学-工程:生物医学
CiteScore
6.50
自引率
14.30%
发文量
409
审稿时长
2 months
期刊介绍: The development and application of theoretical, computational and experimental physics to medicine, physiology and biology. Topics covered are: therapy physics (including ionizing and non-ionizing radiation); biomedical imaging (e.g. x-ray, magnetic resonance, ultrasound, optical and nuclear imaging); image-guided interventions; image reconstruction and analysis (including kinetic modelling); artificial intelligence in biomedical physics and analysis; nanoparticles in imaging and therapy; radiobiology; radiation protection and patient dose monitoring; radiation dosimetry
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信